+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kidney Transplant Rejection R&D Pipeline Analysis Report, Q4 2020

  • PDF Icon

    Report

  • 154 Pages
  • October 2020
  • Region: Global
  • VPA Research
  • ID: 5178670
Kidney Transplant Rejection Pipeline Overview

The Q4 Kidney Transplant Rejection pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Kidney Transplant Rejection, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Kidney Transplant Rejection Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Kidney Transplant Rejection disease overview, Kidney Transplant Rejection types, Kidney Transplant Rejection symptoms, causes, and FDA/EMA approved treatment options.

Kidney Transplant Rejection Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Kidney Transplant Rejection indication. The report presents near-term and long-term pipeline development trends and potential insights.

Kidney Transplant Rejection Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 30 companies. Business profiles and contact details of the companies actively perusing Kidney Transplant Rejection pipeline are assessed.

Kidney Transplant Rejection R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Kidney Transplant Rejection discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Kidney Transplant Rejection companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Kidney Transplant Rejection pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Kidney Transplant Rejection Pipeline Market News and Developments during 2020

The Kidney Transplant Rejection industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Kidney Transplant Rejection Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage
  • Kidney Transplant Rejection pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
  • Company-company partnerships, company-institute partnerships, and investment details of companies are included
  • 30 companies are included including AlphaMab Co Ltd, Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Corline Biomedical AB, Gilead Sciences Inc, Hansa Medical AB, Helocyte Biosciences Inc, Hillhurst Biopharmaceuticals Inc, Idogen AB, ITB Med AB, JN Biosciences LLC, Kiniksa Pharmaceuticals Ltd, Kyowa Hakko Kirin Co Ltd, Mabtech Ltd, Medeor Therapeutics Inc, MyeloRx LLC, Nekonal Sarl, NextCell Pharma AB, Novartis AG, OSE Immunotherapeutics, Pharmicell Co Ltd, Talaris Therapeutics Inc, TolerogenixX GmbH, Tract Therapeutics Inc, TxCell SA, Veloxis Pharmaceuticals AS, Viela Bio Inc, Xenothera,
  • Disease overview, Pipeline trends, market analysis, and other developments
  • Potential licensing/new business opportunities in Kidney Transplant Rejection pipeline market

Highlights
  • Global coverage of companies and pipeline agents
  • 2020 Trends, market analysis, and developments
  • Potential growth opportunities
  • Comprehensive details of drug candidates

Reasons to Buy
  • Drive pipeline research and commercial assessment
  • Assess most promising drug candidates and stay ahead of the competition
  • Strengthen your pipeline through identifying business expansion and acquisition opportunities
  • Develop new candidates based on most focused targets and mechanism of actions

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Kidney Transplant Rejection Pipeline Trends and Insights
2.1 Dominant Phase type of Kidney Transplant Rejection Pipeline, 2020
2.2 Most focused Mechanism of Action in Kidney Transplant Rejection Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Kidney Transplant Rejection pipeline
2.5 Active Companies Developing Kidney Transplant Rejection pipeline
3. Kidney Transplant Rejection Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. Kidney Transplant Rejection Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
  • AlphaMab Co Ltd
  • Amgen Inc
  • Amyndas Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Corline Biomedical AB
  • Gilead Sciences Inc
  • Hansa Medical AB
  • Helocyte Biosciences Inc
  • Hillhurst Biopharmaceuticals Inc
  • Idogen AB
  • ITB Med AB
  • JN Biosciences LLC
  • Kiniksa Pharmaceuticals Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Mabtech Ltd
  • Medeor Therapeutics Inc
  • MyeloRx LLC
  • Nekonal Sarl
  • NextCell Pharma AB
  • Novartis AG
  • OSE Immunotherapeutics
  • Pharmicell Co Ltd
  • Talaris Therapeutics Inc
  • TolerogenixX GmbH
  • Tract Therapeutics Inc
  • TxCell SA
  • Veloxis Pharmaceuticals AS
  • Viela Bio Inc
  • Xenothera

5. Kidney Transplant Rejection Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. Kidney Transplant Rejection Pipeline Market News and Developments during 2020
7. Appendix
7.1 About the Publisher
7.2 Sources and Research Methodology

Companies Mentioned

  • AlphaMab Co Ltd
  • Amgen Inc
  • Amyndas Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Corline Biomedical AB
  • Gilead Sciences Inc
  • Hansa Medical AB
  • Helocyte Biosciences Inc
  • Hillhurst Biopharmaceuticals Inc
  • Idogen AB
  • ITB Med AB
  • JN Biosciences LLC
  • Kiniksa Pharmaceuticals Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Mabtech Ltd
  • Medeor Therapeutics Inc
  • MyeloRx LLC
  • Nekonal Sarl
  • NextCell Pharma AB
  • Novartis AG
  • OSE Immunotherapeutics
  • Pharmicell Co Ltd
  • Talaris Therapeutics Inc
  • TolerogenixX GmbH
  • Tract Therapeutics Inc
  • TxCell SA
  • Veloxis Pharmaceuticals AS
  • Viela Bio Inc
  • Xenothera